Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study
- 1 December 2010
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 9 (5), 282-289
- https://doi.org/10.3816/ccc.2010.n.041
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL StudyJournal of Clinical Oncology, 2008
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Trends in cancer mortality in the Americas, 1970–2000Annals of Oncology, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Obesity trends and determinant factors in Latin AmericaCadernos de Saude Publica, 2003
- Obesity prevalence and trends in Latin‐American countriesObesity Reviews, 2001